A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization
- PMID: 20035614
- PMCID: PMC2971647
- DOI: 10.1089/adt.2009.0217
A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization
Abstract
Binding of hepatitis C virus (HCV) RNA to core, the capsid protein, results in the formation of the nucleocapsid, the first step in the assembly of the viral particle. A novel assay was developed to discover small molecule inhibitors of core dimerization. This assay is based on time-resolved fluorescence resonance energy transfer (TR-FRET) between anti-tag antibodies labeled with either europium cryptate (Eu) or allophycocyanin (XL-665). The N-terminal 106-residue portion of core protein (core106) was tagged with either glutathione-S-transferase (GST) or a Flag peptide. Tag-free core106 was selected as the reference inhibitor. The assay was used to screen the library of pharmacologically active compounds (LOPAC) consisting of 1,280 compounds and a 2,240-compound library from the Center for Chemical Methodology and Library Development at Boston University (CMLD-BU). Ten of the 28 hits from the primary TR-FRET run were confirmed in a secondary amplified luminescent proximity homogeneous assay (ALPHA screen). One hit was further characterized by dose-response analysis yielding an IC(50) of 9.3 microM. This 513 Da compound was shown to inhibit HCV production in cultured hepatoma cells.
Figures







Similar articles
-
Peptide inhibitors of hepatitis C virus core oligomerization and virus production.J Gen Virol. 2009 Jun;90(Pt 6):1319-1328. doi: 10.1099/vir.0.008565-0. Epub 2009 Mar 4. J Gen Virol. 2009. PMID: 19264632
-
Cell-based hepatitis C virus infection fluorescence resonance energy transfer (FRET) assay for antiviral compound screening.Curr Protoc Microbiol. 2010 Aug;Chapter 17(1):Unit 17.5.. doi: 10.1002/9780471729259.mc1705s18. Curr Protoc Microbiol. 2010. PMID: 20812217 Free PMC article.
-
Identification of Compounds Targeting Hepatitis B Virus Core Protein Dimerization through a Split Luciferase Complementation Assay.Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01302-18. doi: 10.1128/AAC.01302-18. Print 2018 Dec. Antimicrob Agents Chemother. 2018. PMID: 30224531 Free PMC article.
-
Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication.Antimicrob Agents Chemother. 2016 Mar 25;60(4):2195-208. doi: 10.1128/AAC.02574-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26810656 Free PMC article.
-
Compound-Mediated Assay Interferences in Homogeneous Proximity Assays.2020 Feb 1. In: Markossian S, Grossman A, Baskir H, Arkin M, Auld D, Austin C, Baell J, Brimacombe K, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Grotegut S, Hall MD, Hoare S, Inglese J, Iversen PW, Lal-Nag M, Li Z, Manro JR, McGee J, Norvil A, Pearson M, Riss T, Saradjian P, Sittampalam GS, Tarselli MA, Trask OJ Jr, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–. 2020 Feb 1. In: Markossian S, Grossman A, Baskir H, Arkin M, Auld D, Austin C, Baell J, Brimacombe K, Chung TDY, Coussens NP, Dahlin JL, Devanarayan V, Foley TL, Glicksman M, Gorshkov K, Grotegut S, Hall MD, Hoare S, Inglese J, Iversen PW, Lal-Nag M, Li Z, Manro JR, McGee J, Norvil A, Pearson M, Riss T, Saradjian P, Sittampalam GS, Tarselli MA, Trask OJ Jr, Weidner JR, Wildey MJ, Wilson K, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004–. PMID: 32045180 Free Books & Documents. Review.
Cited by
-
Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase.J Gen Virol. 2011 Jan;92(Pt 1):101-11. doi: 10.1099/vir.0.023325-0. Epub 2010 Sep 29. J Gen Virol. 2011. PMID: 20881089 Free PMC article.
-
Potential treatment options and future research to increase hepatitis C virus treatment response rate.Hepat Med. 2010 Oct;2010(2):125-145. doi: 10.2147/HMER.S7193. Hepat Med. 2010. PMID: 21331152 Free PMC article.
-
High-throughput screening and rapid inhibitor triage using an infectious chimeric Hepatitis C virus.PLoS One. 2012;7(8):e42609. doi: 10.1371/journal.pone.0042609. Epub 2012 Aug 6. PLoS One. 2012. PMID: 22880053 Free PMC article.
-
Direct binding of a hepatitis C virus inhibitor to the viral capsid protein.PLoS One. 2012;7(2):e32207. doi: 10.1371/journal.pone.0032207. Epub 2012 Feb 28. PLoS One. 2012. PMID: 22389688 Free PMC article.
-
Potent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents.Bioorg Med Chem Lett. 2011 Apr 15;21(8):2198-202. doi: 10.1016/j.bmcl.2011.03.014. Bioorg Med Chem Lett. 2011. PMID: 21440437 Free PMC article.
References
-
- WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 1997;72:341–344. - PubMed
-
- Giannini C. Brechot C. Hepatitis C virus biology. Cell Death Differ. 2003;10(Suppl. 1):S27–S38. - PubMed
-
- Choo Q. Kuo G. Weiner A. Overby L. Bradley D. Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359. - PubMed
-
- McGovern BH. Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr. 2007;45(Suppl 2):S47–S56. - PubMed
-
- Cristina J. Moreno-del Pilar M. Moratorio G. Hepatitis C virus genetic variability in patients undergoing antiviral therapy. Virus Res. 2007;127(2):185–194. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials